Search Results for

R3767-ONC-22122

A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA

Continue Reading »

---

A091903 (JIT)

A Randomized Phase II Trial of Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Mucosal Melanoma

Continue Reading »

---

S2101 (Suspended)

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study (Suspended)

Continue Reading »

---

Search Again

• All Trial Categories Amyloidosis  (1) Bladder/Urinary Tract Cancer  (2)    Adjuvant  (1)    Metastatic  (1) Brain  (5)    Other Brain Tumors  (2) Breast  (8)    Breast Cancer Neoadjuvant  (2) Cancer Control/Symptom Management  (15) Colorectal Cancer  (1) Esophageal Cancer  (3) Gall Bladder/ Biliary Tract Cancer  (1) Gastric Cancer  (2) Head/Neck Cancer  (6) Leukemia  (2)    Acute Myeloid Leukemia (AML)  (1)    B-Cell Chromic Lymphocytic Leukemia (CLL) / Small Ly  (1) Lung Cancer  (12)    Non-Small Cell Lung Cancer  (9)       1st Line Metastatic, Stage3b with Maligned Effusion or Stage 4 Disease at Presentation or Recurrence  (1)    Small Cell Lung Cancer  (3) Lymphoma  (3)    Non-Hodgkin’s Lymphoma  (3)       Diffuse Large B-Cell Lymphoma  (1)       Follicular Lymphoma  (2) MATCH Trial  (3) Melanoma  (3)    Metastatic  (1) Misc. Gynecology  (3) Multiple Myeloma  (1) Ovarian  (1) Pancreatic  (6)    Metastatic Disease  (1) Prostate  (9) Renal Cell/Kidney Cancer  (2) Sarcoma  (1) Thyroid  (1)